As NK cell dysfunction and impairment promotes tumor immune evasion in NSCLC, emerging therapies have focused on restoring normal function of NK cells by means of cytokine supplementation, blockade of inhibitory receptors, and neutralization of immunosuppressive cytokines such as TGF-β [73]. The gene discussed is TGFB1; the disease is non-small cell lung carcinoma.